drugset / Trial / NCT00840203

Mesalamine 4 gm/60 mL Rectal Enema

NCT00840203

Phase 1 Completed 72 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to evaluate the relative bioavailability of the test formulation of mesalamine suspension rectal enema with the already marketed reference formulation Rowasa® in healthy, adult subjects.

Timeline

Start
2003-05
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 4 g Rectal

Indications

No indication recorded.